Effect of pegylation on pharmaceuticals (Q35075776)

6 August 2017

1 reference

title

Effect of pegylation on pharmaceuticals (English)

1 reference

6 August 2017

J Milton Harris

1

1 reference

6 August 2017

Robert B Chess

series ordinal

2

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Nature Reviews Drug Discovery

6 August 2017

published in

1 reference

6 August 2017

volume

2

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

214-221

1 reference

Chemistry for peptide and protein PEGylation

6 August 2017

cites work

1 reference

Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity.

31 March 2020

1 reference

Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein.

31 March 2020

1 reference

Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice

31 March 2020

1 reference

Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins

31 March 2020

1 reference

Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM

31 March 2020

1 reference

Pegylation: a novel process for modifying pharmacokinetics

31 March 2020

1 reference

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.

31 March 2020

1 reference

A branched monomethoxypoly(ethylene glycol) for protein modification

31 March 2020

1 reference

Development of pegylated interferons for the treatment of chronic hepatitis C.

31 March 2020

1 reference

Characterization and stability of N-terminally PEGylated rhG-CSF.

31 March 2020

1 reference

LABORATORY SYNTHESIS OF POLYETHYLENE GLYCOL DERIVATIVES

31 March 2020

1 reference

New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine

31 March 2020

1 reference

Synthesis of poly(ethylene oxide) with heterobifunctional reactive groups at its terminals by an anionic initiator

31 March 2020

1 reference

PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years

31 March 2020

1 reference

L-asparaginase and PEG asparaginase--past, present, and future

31 March 2020

1 reference

Pegaspargase: an alternative?

31 March 2020

1 reference

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

31 March 2020

1 reference

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

31 March 2020

1 reference

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

31 March 2020

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C.

31 March 2020

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

31 March 2020

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

31 March 2020

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

31 March 2020

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

31 March 2020

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

31 March 2020

1 reference

Successful treatment of resistant acromegaly with a growth hormone receptor antagonist

31 March 2020

1 reference

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

31 March 2020

1 reference

PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases

31 March 2020

1 reference

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

31 March 2020

1 reference

Clinical uses of pegylated pharmaceuticals in oncology

31 March 2020

1 reference

Pegfilgrastim: a new therapy to prevent neutropenic fever

31 March 2020

1 reference

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

31 March 2020

1 reference

Liposome-based drug delivery in breast cancer treatment

31 March 2020

1 reference

Novel degradable poly(ethylene glycol) hydrogels for controlled release of protein

31 March 2020

1 reference

A novel synthetic sealant to treat air leaks at cardiac reoperation

31 March 2020

1 reference

Trial of a novel synthetic sealant in preventing air leaks after lung resection

31 March 2020

1 reference

Evaluation of a sprayable polyethylene glycol adhesion barrier in a porcine efficacy model

31 March 2020

1 reference

Effects of PEG conjugation on insulin properties

31 March 2020

1 reference

Formatting antibody fragments to mediate specific therapeutic functions

31 March 2020

1 reference

Pathophysiological and histomorphological evaluation of polyacryloylmorpholine vs polyethylene glycol modified superoxide dismutase in a rat model of ischaemia/reperfusion injury

31 March 2020

1 reference

Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery

31 March 2020

1 reference

Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD1033

1 reference

6 August 2017

1 reference